LY2811376 supplier|cas 1194044-20-6 |DC Chemicals|Supplier|Price|Buy  

DC Chemials Supply: LY2811376 supplier,cas 1194044-20-6, Cat No. DC5180, In stock

Contact:sales@dcchemicals.com, order@dcchemicals.com,info@dcchemicals.com,Tel: +86-21-61454686;Fax:+86-21-61642470

Product name: LY2811376, Synonym:　LY 2811376;LY-2811376, Cat No. DC5180, Cas: 1194044-20-6, Chemical Name:N/A, Molecular Formula: C15H14F2N4S, MW: 320.36

LY2811376,cas 1194044-20-6, Purity: >98%. Best Price and quality in the market,DC Chemicals,Primary Manufacturer, confirmed by HNMR and HPLC. LY2811376 is the first orally available non-peptidicβ-secretase(BACE1) inhibitor with IC50 of 239 nM-249 nM, that act to decreaseAβ secretion with EC50 of 300 nM, demonstrated to have 10-fold selectivity towards BACE1 over BACE2, and more than 50-fold inhibition over other aspartic proteases including cathepsin D, pepsin, or renin. Phase 1.LY2811376 is a BACE1 inhibitor with marked Ab-lowering effects in animal models. Oral administration of LY2811376 to PDAPP mice produced dose-dependent reductions in brain Abeta, C99 and sAPPb. Brain Abeta levels were decreased 50% relative to vehicle-treated groups three hours after a 10 mg/kg dose of LY2811376. LY2811376 has pharmacologic properties sufficient to elicit robust BACE1 inhibition in vivo. The first orally available non-peptidic β-secretase inhibitor, LY2811376, was identified by fragment-based screening, lowered Aβ levels in a mouse model of Alzheimer's disease as well as in normal dogs. In healthy volunteers LY2811376 was safe and well tolerated and produced long-lasting reductions in Aβ levels. LY2811376 produced sustained and robust reductions in plasma and CSF Ab in subjects, confirming proof of mechanism. While the clinical development of LY2811376 is on hold, development of potent, clinically well-tolerated BACE1 inhibitors for the treatment of Alzheimer's disease appears plausible.